TNFRSF8 and Hodgkins lymphoma: In a phase II pivotal study of BV in patients with relapsed or refractory CD30-positive Hodgkin’s lymphomas, the ORR was 75% with CR in 34% of patients [21], which is replicated in the current study, where the ORR was the same, with a high number of HL patients achieving CR as a best response (68.8%).